Join our daily newsletter At The Bell to receive exclusive market insights
- Trajan Group (TRJ) enters a deal to secure equity and a board position in HumanKind Ventures which trades as ‘Forth’ which provides at-home testing services for people to track and optimise their health
- For £705,002 (A$1.3 million), Trajan will get a percentage of the share capital as follows: 9.55 per cent non-diluted, 8.41 per cent fully diluted and a 9.85 per cent voting interest
- Trajan is also appointing General Manager for the Separation Science Business Unit Kayte Parlevliet to HumanKind Ventures’ Board
- TRJ says the investment is strategic as the companies share the same values in helping people engage and being proactive with their health
- Company shares end the day 2.41 per cent in the red to close at $3.24
Trajan Group (TRJ) has entered a binding agreement to secure equity and a board position in UK-based HumanKind Ventures.
HumanKind Ventures, which trades as Forth, provides a range of at-home sampling and testing services to enable people to track and optimise key internal biomarkers without the need to visit a GP.
Users can also access Forth’s ‘industry-leading’ app which features a dashboard where users can view their measurements, hormone levels, diet, stress levels, and more.
Forth CEO and Co-founder Sarah Bolt commented on the company’s mission and the investment.
“Our mission at Forth is simple – to give people a better understanding of their own body using a combination of science and technology,” she said.
“This investment will enable us to launch Female Hormone Mapping and also develop more unique and insightful products to help people engage proactively with their health. Trajan is a perfect partner as we share a focus on using science to advance preventative health.”
Trajan will pay £705,002 (A$1.3 million) which results in the issue of 235,298 new shares, giving Trajan a percentage of the share capital as follows: 9.55 per cent non-diluted, 8.41 per cent fully diluted and a 9.85 per cent voting interest.
As part of the agreement, Trajan’s General Manager for the Separation Science Business Unit, Kayte Parlevliet, will sit on the HumanKind Ventures Board to provide an opportunity to explore future collaborations.
Trajan CEO and Managing Director Stephen Tomisich commented on the deal.
“We share common values around delivering good science that helps people achieve better health outcomes. We are both intensely focused on delivering impact and working together we believe we will do just that. Trajan is currently engaged in multiple investment and acquisition opportunities. The stake in Forth is one example that is relatively small in scale but of significant strategic importance.”
Overall, Trajan believes the investment aligns with its strategy towards direct-to-consumer health technology.
Company shares ended the day 2.41 per cent in the red to close at $3.24.
